This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Jacobson, M A
Right arrow Articles by Mills, J
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jacobson, M A
Right arrow Articles by Mills, J

 Previous Article  |  Next Article 

Antimicrob Agents Chemother. 1989 May; 33(5): 736-741

Foscarnet treatment of cytomegalovirus retinitis in patients with the acquired immunodeficiency syndrome.

M A Jacobson, J J O'Donnell and J Mills

Department of Medicine, University of California, San Francisco.

ABSTRACT

Ten patients with acquired immunodeficiency syndrome with newly diagnosed cytomegalovirus (CMV) retinitis were treated with an induction regimen of intravenous foscarnet, 60 mg/kg of body weight, administered as a 2-h infusion and repeated every 8 h for 14 days. At the end of induction, 9 of 10 patients had stabilized (no new retinal lesions and stable old lesions [7 patients]) or improved (decreased retinal opacification [2 patients]). All eight patients with CMV in urine or blood upon entry into the study had negative urine and blood cultures at the end of induction. After induction therapy, seven patients continued maintenance foscarnet therapy, 60 mg/kg as a single daily infusion, 5 days/week. In six patients, retinal lesions increased in size after 2 to 32 weeks of maintenance therapy. One was invaluable because a retinal detachment developed. Only 9 of 42 blood and urine cultures obtained during maintenance foscarnet therapy yielded CMV, compared with 7 of 14 obtained prior to the initiation of foscarnet induction therapy (P = 0.04). Foscarnet toxicity was mild and infrequent: elevation in serum creatinine by 0.5 to 1.3 mg/dl over the base line (two patients), muscle twitching (three patients), hemoglobin decrease by 1 mg/dl (two patients), nausea (two patients), absolute neutrophil count decrease by 50% (one patient), rise in serum phosphorus to greater than 5.5 mg/dl (four patients), and proteinuria (two patients). Intermittently administered intravenous foscarnet appears to be an effective, relatively nontoxic therapy for CMV retinitis. Additional studies to determine the optimal dosage for maintenance therapy are needed, as are comparative trials with ganciclovir.

Antimicrob Agents Chemother. 1989 May; 33(5): 736-741




This article has been cited by other articles:

  • Bochot, A., Fattal, E., Boutet, V., Deverre, J. R., Jeanny, J. C., Chacun, H., Couvreur, P. (2002). Intravitreal Delivery of Oligonucleotides by Sterically Stabilized Liposomes. IOVS 43: 253-259 [Abstract] [Full Text]  
  • Huycke, M. M., Naguib, M. T., Stroemmel, M. M., Blick, K., Monti, K., Martin-Munley, S., Kaufman, C. (2000). A Double-Blind Placebo-Controlled Crossover Trial of Intravenous Magnesium Sulfate for Foscarnet-Induced Ionized Hypocalcemia and Hypomagnesemia in Patients with AIDS and Cytomegalovirus Infection. Antimicrob. Agents Chemother. 44: 2143-2148 [Abstract] [Full Text]  
  • Musch, D. C., Martin, D. F., Gordon, J. F., Davis, M. D., Kuppermann, B. D., The Ganciclovir Implant Study Group, (1997). Treatment of Cytomegalovirus Retinitis with a Sustained-Release Ganciclovir Implant. NEJM 337: 83-90 [Abstract] [Full Text]  
  • Jacobson, M. A. (1997). Treatment of Cytomegalovirus Retinitis in Patients with the Acquired Immunodeficiency Syndrome. NEJM 337: 105-114 [Full Text]  
  • Spector, S. A., McKinley, G. F., Lalezari, J. P., Samo, T., Andruczk, R., Follansbee, S., Sparti, P. D., Havlir, D. V., Simpson, G., Buhles, W., Wong, R., Stempien, M. J., The Roche Cooperative Oral Ganciclovir Study Group, (1996). Oral Ganciclovir for the Prevention of Cytomegalovirus Disease in Persons with AIDS. NEJM 334: 1491-1497 [Abstract] [Full Text]  
  • Drew, W. L., Ives, D., Lalezari, J. P., Crumpacker, C., Follansbee, S. E., Spector, S. A., Benson, C. A., Friedberg, D. N., Hubbard, L., Stempien, M. J., Shadman, A., Buhles, W., The Syntex Cooperative Oral Ganciclovir Study Grou, (1995). Oral Ganciclovir as Maintenance Treatment for Cytomegalovirus Retinitis in Patients with AIDS. NEJM 333: 615-620 [Abstract] [Full Text]  
  • Studies of Ocular Complications of AIDS Research G, , AIDS Clinical Trials Group, , Lewis, R. A., Clogston, P., Fainstein, V., Gross, R., Samo, T., Tuttle, C., Jabs, D. A., Apuzzo, L., Bartlett, J., Coleson, L., Dunn, J. P., Eldred, L., Feinberg, J., Flynn, T., King, R., Leslie, J., Barron, B., Greenspan, D., Le-Count, C., Peyman, G., Franklin, R., Heinemann, M.-H., Polsky, B., Squires, K., Wise-Campbell, S., Friedman, A. H., Cheung, T. W., Justin, N., Teich, S., Sacks, H., Severin, C., Friedberg, D. N., Addessi, A., Dieterich, D., Frost, K., Weinberg, D., Jampol, L., Murphy, R., Naughton, K., Henderly, D., Holland, G. N., Chafey, S., Fall, H., Hardy, W. D., Kimbrell, C., MacArthur, L. J., Freeman, W. R., Meixnert, L., Peterson, T. J., Quiceno, J. I., Rickman, L., Simanello, M. A., Spector, S., O'Donnell, J., Hoffman, J., Irvine, A., Jacobson, M., Larson, J., Seiff, S., Wanner, M., Davis, J., Chuang, E., Espinal, M., Mendez, P., Vandenbroucke, R., Cheeseman, S. H., Gittinger, J., Haubrich, R., Kachadoorian, H., Tolson, K., Jabs, D. A., Kline, J. M., Klemm, A. C., Stevens, M., Webb, R., Brown-Bellamy, J., Markowitz, J. A., Meinert, C. L., Binder, K. L., Brookmeyer, R., Brown, V. E., Collison, B. J., Dodge, J., Donithan, M., Fink, N., Gerczak, C., Holbrook, J. T., Isaacson, M. R., Jones, C. P., Levine, C. R., Min, Y.-I, Meinert, J. L., Owens, R. M., Nowakowski, D. J., Saah, A., Sandford, G. R., Singer, S., Smith, M., Sternberg, A. L., Tonascia, J., Van Natta, M. L., Davis, M. D., Agres-Segal, M., Armstrong, J., Brothers, R., Freitag, G., Hubbard, L., Hurlburt, D., Kastorff, L., Magli, Y., Miner, K., Thomas, S., Vanderhoof-Young, M., Stewart, G., Hughes, R., Welch, L., Mowery, R., Ellenberg, S., Korvick, J., Jabs, D. A., Davis, M. D., Meinert, C. L., Mowery, R., Jabs, D. A., Barron, B., Clark, T., Clogston, P. S., Davis, M. D., Dieterich, D., Espinal, M., Freeman, W., Hardy, W. D., Holbrook, J. T., Holland, G. N., Hubbard, L., Korvick, J., Lewis, R. A., Markowitz, J. A., Meinert, C. L., Mowery, R., Polsky, B., Tonascia, J., Jabs, D. A., Davis, M. D., Ellenberg, S., Feinberg, J., Jacobson, M., Korvick, J., Meinert, C. L., Mowery, R., Sattler, F., Tonascia, J., Jordan, C., Mills, J., Brown, B. W. Jr, Conway, B., Grizzle, J., Nussenblatt, R., Phair, J., Smith, H., Davis, M. D., Ellenberg, S., Jabs, D. A., Meinert, C. L., Mowery, R., Tonascia, J. (1995). Morbidity and Toxic Effects Associated With Ganciclovir or Foscarnet Therapy in a Randomized Cytomegalovirus Retinitis Trial. Arch Intern Med 155: 65-74 [Abstract]  
  • Martin, D. F., Parks, D. J., Mellow, S. D., Ferris, F. L., Walton, R. C., Remaley, N. A., Chew, E. Y., Ashton, P., Davis, M. D., Nussenblatt, R. B. (1994). Treatment of Cytomegalovirus Retinitis With an Intraocular Sustained-Release Ganciclovir Implant: A Randomized Controlled Clinical Trial. Arch Ophthalmol 112: 1531-1539 [Abstract]  
  • Kuppermann, B. D., Flores-Aguilar, M., Quiceno, J. I., Rickman, L. S., Freeman, W. R. (1993). Combination Ganciclovir and Foscarnet in the Treatment of Clinically Resistant Cytomegalovirus Retinitis in Patients With Acquired Immunodeficiency Syndrome. Arch Ophthalmol 111: 1359-1366 [Abstract]  
  • Jabs, D. A. (1992). Treatment of Cytomegalovirus Retinitis--1992. Arch Ophthalmol 110: 185-187 [Abstract]  
  • Palestine, A. G., Polis, M. A., De Smet, M. D., Baird, B. F., Falloon, J., Kovacs, J. A., Davey, R. T., Zurlo, J. J., Zunich, K. M., Davis, M., Hubbard, L., Brothers, R., Ferris, F. L., Chew, E., Davis, J. L., Rubin, B. I., Mellow, S. D., Metcalf, J. A., Manischewitz, J., Minor, J. R., Nussenblatt, R. B., Masur, H., Lane, H. C. (1991). A Randomized, Controlled Trial of Foscarnet in the Treatment of Cytomegalovirus Retinitis in Patients with AIDS. ANN INTERN MED 115: 665-673 [Abstract]  
  • Farese, R. V. Jr., Schambelan, M., Hollander, H., Stringari, S., Jacobson, M. A. (1990). Nephrogenic Diabetes Insipidus Associated with Foscarnet Treatment of Cytomegalovirus Retinitis. ANN INTERN MED 112: 955-956 [Abstract]  


Copyright © 2010 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»